Compare GORO & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GORO | ACOG |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.3M | 130.9M |
| IPO Year | N/A | N/A |
| Metric | GORO | ACOG |
|---|---|---|
| Price | $0.73 | $5.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.38 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.2M | 98.7K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,430,000.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $117.97 | $101.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $3.75 |
| 52 Week High | $1.18 | $11.54 |
| Indicator | GORO | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 39.60 |
| Support Level | $0.62 | $5.66 |
| Resistance Level | $0.83 | $6.18 |
| Average True Range (ATR) | 0.06 | 0.45 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 52.29 | 22.68 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.